Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

Sofi-cel, an allogeneic CAR-T therapy, targets CD7 and uses CRISPR/Cas9 to prevent fratricide and reduce graft-versus-host disease risk. The FDA's breakthrough therapy designation facilitates ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved ziftomenib for adult patients with relapsed or refractory acute myeloid leukemia with a ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

FDA authorized teclistamab + daratumumab hyaluronidase for RRMM after ≥1 prior line with PI and IMiD exposure, expanding access earlier in the treatment sequence. Traditional approval also formalized ...

Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, showing significant PFS and OS benefits in the DREAMM-7 trial. The drug ...

Monjuvi in combination with lenalidomide and rituximab significantly improved PFS in patients with relapsed/refractory follicular lymphoma. The Food and Drug Administration (FDA) has approved Monjuvi ...

During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.